HPN217

· Harpoon Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HPN217, covering 2025-12-05 to 2025-12-05. Get the full timeline:

Most recent: Clinical Trial Update: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) [Phase 1]